How a panoply of international programs safeguards our research budget

29 September 2017

​As a world-class research institute, it goes without saying that a lot of our research income depends on European and wider international funding programs. The impressive numbers below don’t just prove the importance of our worldwide collaborations, they also underline our unwavering international visibility.

VIB teams up with Horizon 2020, the EU program for Research and Innovation, from 2013-2020:

  • H2020 accounts for 75% of our international funding
  • Signed 44 H2020 grants involving 226 collaborating organizations in 30 different countries
  • Individual bottom-up ERC (32) grants and Marie Curie (MSCA) postdoc grants (8) are the most prestigious grants for VIB and are important to attract international researchers to VIB.
  • Partner in 17 collaborative H2020 projects on health and climate change
  • Partner in 6 MSCA International Training Networks (ITN or RISE) for PhD students

Our other international funding bodies:

  • The US’s National Institutes of Health (NIH)
  • The Human Frontier Science Program (HFSP)
  • The Bill & Melinda Gates Foundation (BMGF)
  • And many more

150 International grants signed at VIB since 2013


Massimiliano Mazzone (VIB – KU Leuven Center for Cancer Biology) recently obtained an MSCA-ITN grant. “To be part of this MSCA-ITN network is a great honor and recognition for me. It embeds the lab in an international context but most importantly META-CAN (the name of this network) highlights a common mission from different top labs that are joining forces to address important questions on the metabolic cross-talk within different cancer compartments. We aim to understand mechanisms of resistance for standard care and also propose new therapeutic options. This is a big opportunity; it will bridge expertise and will launch coaching programs. META-CAN is a training network: PhD students enrolled in this program will come along and become specialists in tumor-stroma interactions: they will have chances to spend time abroad, to meet the top experts from other labs belonging to the network, to attend lectures and workshops, and to have their own contacts with industrial partners, bridging pharma with academia. I am really excited to be part of this entire research project.“


Go back to the overview 'Stronger through diversity'



Massimiliano Mazzone (VIB – KU Leuven Center for Cancer Biology)